NervGen Pharma Grants Stock Options

Rhea-AI Summary

NervGen Pharma (OTCQB: NGENF), a clinical-stage biotech company focused on neuroreparative therapeutics, has announced the granting of 600,000 incentive stock options. The options are structured as follows:

- 500,000 options granted to Directors, exercisable at $4.00 per share for 5 years, vesting quarterly over 1 year
- 100,000 options granted to employees, exercisable at $4.00 per share for 10 years, vesting semi-annually over 4 years

All options comply with TSX Venture Exchange policies and the company's stock option plan.

News Market Reaction

+8.83%

1 alert

+8.83% News Effect

On the day this news was published, NGENF gained 8.83%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Vancouver, British Columbia--(Newsfile Corp. - May 16, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuroreparative therapeutics, today announced that it has granted 600,000 incentive stock options (the "Options") to directors and employees of the company. The Options are exercisable at a price of $4.00 per share. 500,000 of the Options were granted to the company's Directors and are exercisable for a period of five years and vest equally every three months over a one-year period. 100,000 of the Options were granted to employees and are exercisable for a period of ten years and vest equally every six months over a four-year period. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the company's stock option plan.

About NervGen

NervGen (TSXV: NGEN) (OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company is testing the clinical efficacy of its lead candidate, NVG-291, in a Phase 1b/2a clinical trial in spinal cord injury and has initiated preclinical test of concept evaluation of our pipeline candidate, NVG-300, in models of ischemic stroke and spinal cord injury. For more information, visit www.nervgen.com and follow NervGen on X and LinkedIn for the latest news on the company.

Contacts

Huitt Tracey, Investor Relations
htracey@nervgen.com
604.537.2094

Bill Adams, Chief Financial Officer
info@nervgen.com
778.731.1711

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/252471

FAQ

What is the exercise price of NGENF's newly granted stock options?

The stock options granted by NervGen Pharma (NGENF) are exercisable at a price of $4.00 per share.

How many stock options did NervGen Pharma (NGENF) grant to directors in May 2025?

NervGen Pharma granted 500,000 stock options to its Directors, vesting equally every three months over a one-year period.

What is the vesting schedule for NGENF's employee stock options granted in May 2025?

The 100,000 employee stock options vest equally every six months over a four-year period.

What is the expiration period for the stock options granted by NGENF to directors and employees?

Directors' options are exercisable for 5 years, while employees' options are exercisable for 10 years.